Efficacy of PolyMPC-DOX prodrugs in 4T1 tumor-bearing mice

Molecular Pharmaceutics

Volumn 11, Issue 5, 2014, Pages 1715-1720

  McRae Page, Samantha ^a   Henchey, Elizabeth ^b   Chen, Xiangji ^a   Schneider, Sallie ^b   Emrick, Todd ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Pioneer Valley Life Sciences Institute   (United States)

Author keywords

doxorubicin; drug delivery; poly(methacryloyloxyethyl phosphorylcholine); polymer prodrug; polymer drug conjugate

Indexed keywords

DOXORUBICIN; DRUG CARRIER; POLY(2 METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE); POLYMER; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; INFANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; POLYMERS; PRODRUGS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899888587     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500009r     Document Type: Article

References (22)

1. Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
2. Vicent, M. J.; Duncan, R. Polymer conjugates: nanosized medicines for treating cancer Trends Biotechnol. 2006, 24, 39-47
3. Haag, R.; Kratz, F. Polymer therapeutics: Concepts and applications Angew. Chem., Int. Ed. 2006, 45, 1198-1215
4. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vasculature permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284
5. Oh, K. T.; Yin, H.; Lee, E. S.; Bae, Y. H. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms J. Mater. Chem. 2007, 17, 3987-4001
6. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 1989, 49, 4373-4384
7. Engin, K.; Leeper, D. B.; Cater, J. R.; Thistlethwaite, A. J.; Tupchong, L.; McFarlane, J. D. Extracellular pH distribution in human tumors Int. J. Hyperthermia 1995, 11, 211-216
8. Mellman, I.; Fuchs, R.; Helenius, A. Acidification of the endocytic and exocytic pathways Annu. Rev. Biochem. 1986, 55, 663-700
9. Chen, X.; Parelkar, S. S.; Henchey, E.; Schneider, S.; Emrick, T. PolyMPC-Doxorubicin Prodrugs Bioconjugate Chem. 2012, 23, 1753-1763
10. Pulaski, B. A.; Ostrand-Rosenberg, S. Mouse 4T1 Breast Tumor Model Curr. Protoc. Immunol. 2001, 39, 20.2.1-20.2.16
11. Tao, K.; Fang, M.; Alroy, J.; Sahagian, G. G. Imagable 4T1 model for the study of late stage breast cancer BMC Cancer 2008, 8, 228-246
12. Etrych, T.; Sirova, M.; Starovoytova, L.; Rihova, B.; Ulbrich, K. HPMA Copolymer Conjugates of Paclitaxel and Docetaxel with pH-Controlled Drug Release Mol. Pharmaceutics 2010, 7, 1015-1026
13. Liu, Z.; Chen, K.; Davis, C.; Sherlock, S.; Cao, Q.; Chen, X.; Dai, H. Drug delivery with carbon nanotubes for in vivo cancer treatment Cancer Res. 2008, 68, 6652-6660
14. Paraskar, A.; Soni, S.; Basu, S.; Amarasiriwardena, C. J.; Lupoli, N.; Srivats, S.; Roy, R. S.; Sengupta, S. Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy Nanotechnology 2011, 22, 265101
15. Paraskar, A. S.; Soni, S.; Chin, K. T.; Chaudhuri, P.; Muto, K. W.; Berkowitz, J.; Handlogten, M. W.; Alves, N. J.; Bilgicer, B.; Dinulescu, D. M.; Mashelkar, R. A.; Sengupta, S. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 12435-12440
16. Kiew, L. V.; Cheong, S. K.; Ramli, E.; Sidik, K.; Lim, T. M.; Chung, L. Y. Efficacy of Poly-L-Glutamic Acid-Gemcitabine Conjugate in Tumor-Bearing Mice Drug Dev. Res. 2012, 73, 120-129
17. Zhou, L.; Cheng, R.; Tao, H.; Ma, S.; Guo, W.; Meng, F.; Liu, H.; Liu, Z.; Zhong, Z. Endosomal pH-Activatable Poly(ethylene oxide)-graft-Doxorubicin Prodrugs: Synthesis Drug Release, and Biodistribution in Tumor-Bearing Mice Biomacromolecules 2011, 12, 1460-1467
18. Gao, Z.-G.; Tian, L.; Park, I.-S.; Bae, Y. H. Prevention of metastasis in 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles J. Controlled Release 2011, 152, 84-89
19. Kratz, F.; Azab, S.; Zeisig, R.; Fichtner, I.; Warnecke, A. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model Int. J. Pharm. 2013, 441, 499-506
20. Lee, C. C.; Gillies, E. R.; Fox, M. E.; Guillaudeu, S. J.; Frechet, J. M. J.; Dy, E. E.; Szoka, F. C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16649-16654
21. Hilmer, S. N.; Cogger, V. C.; Muller, M.; Le Couteur, D. G. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin Drug Metab. Dispos. 2004, 32, 794-799
22. 2 Ann. Oncol. 2000, 11, 1029-1033